An update from Galmed Pharmaceuticals ( (GLMD) ) is now available.
On April 15, 2025, Galmed Pharmaceuticals announced the discovery of novel pharmacodynamic blood markers for Aramchol, its leading SCD1 inhibitor. These markers, identified in collaboration with Proteas Health, provide insights into Aramchol’s biochemical effects, including reduced inflammation and heart failure markers, potentially expanding its therapeutic applications. This development could enhance clinical decision-making and broaden Galmed’s market reach, offering significant value to stakeholders.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges with no revenue and continuous operational losses. The technical indicators signal a strong bearish trend, and the valuation metrics highlight ongoing unprofitability with a negative P/E ratio. Despite a debt-free balance sheet, the company’s reliance on equity financing amid operational inefficiencies poses substantial risks.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology indications. The company is primarily dedicated to advancing Aramchol, its lead compound, for the treatment of liver diseases and is exploring additional applications in oncological and cardiometabolic indications.
YTD Price Performance: -59.94%
Average Trading Volume: 888,147
Technical Sentiment Signal: Buy
Current Market Cap: $3M
Find detailed analytics on GLMD stock on TipRanks’ Stock Analysis page.